Hyppää sisältöön
    • Suomeksi
    • In English
Trepo
  • Suomeksi
  • In English
  • Kirjaudu
Näytä viite 
  •   Etusivu
  • Trepo
  • TUNICRIS-julkaisut
  • Näytä viite
  •   Etusivu
  • Trepo
  • TUNICRIS-julkaisut
  • Näytä viite
JavaScript is disabled for your browser. Some features of this site may not work without it.

Identification of patients with branch-duct intraductal papillary mucinous neoplasm and very low risk of cancer : multicentre study

Tamburrino, Domenico; de Pretis, Nicolò; Pérez-Cuadrado-Robles, Enrique; Uribarri-Gonzalez, Laura; Ateeb, Zeeshan; Belfiori, Giulio; Maisonneuve, Patrick; Capurso, Gabriele; Vanella, Giuseppe; Petrone, Maria Chiara; Arcidiacono, Paolo Giorgio; Vaalavuo, Yrjo; Frulloni, Luca; Dominguez-Muñoz, J. Enrique; Deprez, Pierre H.; Falconi, Massimo; Del Chiaro, Marco; Crippa, Stefano; Laukkarinen, Johanna (2022-06)

 
Avaa tiedosto
znac103_1.pdf (485.4Kt)
Lataukset: 



Tamburrino, Domenico
de Pretis, Nicolò
Pérez-Cuadrado-Robles, Enrique
Uribarri-Gonzalez, Laura
Ateeb, Zeeshan
Belfiori, Giulio
Maisonneuve, Patrick
Capurso, Gabriele
Vanella, Giuseppe
Petrone, Maria Chiara
Arcidiacono, Paolo Giorgio
Vaalavuo, Yrjo
Frulloni, Luca
Dominguez-Muñoz, J. Enrique
Deprez, Pierre H.
Falconi, Massimo
Del Chiaro, Marco
Crippa, Stefano
Laukkarinen, Johanna
06 / 2022


doi:10.1093/bjs/znac103
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202207045966

Kuvaus

Peer reviewed
Tiivistelmä
BACKGROUND: Different surveillance strategies for patients with low-risk branch-duct (BD) intraductal papillary neoplasm (IPMN) have been described. The aim of this study was to describe the natural history of low-risk BD-IPMN, and to identify risk factors for the development of worrisome features (WF)/high-risk stigmata (HRS) and of pancreatic malignancies. METHODS: This was a multicentre retrospective study of patients with BD-IPMN who were under active surveillance between January 2006 and December 2015. Patients were eligible if they had a low-risk lesion and had a minimum follow-up of 24 months. Outcomes were development of WF/HRS or cytologically/histologically confirmed malignant IPMN. RESULTS: Of 837 patients included, 168 (20 per cent) developed WF/HRS. At the end of the observation time, 132 patients (79 per cent) with WF/HRS were still under surveillance without progression to pancreatic cancer. Factors associated with the development of WF or HRS in multivariable analysis included localized nodules (versus diffuse: hazard ratio (HR) 0.43, 95 per cent c.i. 0.26 to 0.68), cyst size 15-19 mm (versus less than 15 mm: HR 1.88, 1.23 to 2.87) or at least 20 mm (versus less than 15 mm: HR 3.25, 2.30 to 4.60), main pancreatic duct size over 3 mm (versus 3 mm or less: HR 2.17, 1.41 to 3.34), and symptoms at diagnosis (versus no symptoms: HR 2.29, 1.52 to 3.45). Surveillance in an endoscopy-oriented centre was also associated with increased detection of WF or HRS (versus radiology-oriented: HR 2.46, 1.74 to 3.47). CONCLUSION: Conservative management of patients with low-risk BD-IPMN is safe and feasible.
Kokoelmat
  • TUNICRIS-julkaisut [12600]
Kalevantie 5
PL 617
33014 Tampereen yliopisto
oa[@]tuni.fi | Tietosuoja | Saavutettavuusseloste
 

 

Selaa kokoelmaa

TekijätNimekkeetTiedekunta (2019 -)Tiedekunta (- 2018)Tutkinto-ohjelmat ja opintosuunnatAvainsanatJulkaisuajatKokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy
Kalevantie 5
PL 617
33014 Tampereen yliopisto
oa[@]tuni.fi | Tietosuoja | Saavutettavuusseloste